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Prostaglandin D2 Inhibits Wound-Induced Hair
Follicle Neogenesis through the Receptor, Gpr44
Amanda M. Nelson1,5, Dorothy E. Loy2,5, John A. Lawson3,4, Adiya S. Katseff1, Garret A. FitzGerald3,4 and
Luis A. Garza1
Prostaglandins (PGs) are key inflammatory mediators involved in wound healing and regulating hair growth;
however, their role in skin regeneration after injury is unknown. Using wound-induced hair follicle neogenesis
(WIHN) as a marker of skin regeneration, we hypothesized that PGD2 decreases follicle neogenesis. PGE2 and
PGD2 were elevated early and late, respectively, during wound healing. The levels of WIHN, lipocalin-type
prostaglandin D2 synthase (Ptgds), and its product PGD2 each varied significantly among background strains of
mice after wounding, and all correlated such that the highest Ptgds and PGD2 levels were associated with the
lowest amount of regeneration. In addition, an alternatively spliced transcript variant of Ptgds missing exon 3
correlated with high regeneration in mice. Exogenous application of PGD2 decreased WIHN in wild-type
mice, and PGD2 receptor Gpr44-null mice showed increased WIHN compared with strain-matched control mice.
Furthermore, Gpr44-null mice were resistant to PGD2-induced inhibition of follicle neogenesis. In all, these
findings demonstrate that PGD2 inhibits hair follicle regeneration through the Gpr44 receptor and imply that
inhibition of PGD2 production or Gpr44 signaling will promote skin regeneration.
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INTRODUCTION
Scar formation and tissue regeneration are opposite results of
the wound healing process. Although fibrosis is more common
after skin injury, full skin regeneration results in complete
replacement of adnexa and function. Examples of tissue
regeneration in mammalian systems include annual regenera-
tion in deer antlers, ear regeneration following tag removal in
mice and rabbits, and regeneration of amputated digit tips and
liver regeneration in both mice and humans (Han et al., 2005;
Price et al., 2005; Metcalfe et al., 2006; Jia, 2011). In skin, Ito
et al. (2007) fully described and characterized de novo hair
follicle neogenesis that is dependent on Wnt signaling
after full-thickness wounding in mice. These regenerated
hair follicles establish a stem cell population, express hair
follicle differentiation markers, produce a functional hair shaft,
successfully transition through all phases of the hair cycle,
and include associated structures, such as sebaceous glands
(Ito et al., 2007). However, what triggers mammalian
regeneration is not completely understood. Determining
which factors regulate this process may reveal mechanisms
and lead to specifically designed therapies to enhance
regeneration.
Prostaglandins (PGs) are lipid signaling molecules enzyma-
tically derived from arachidonic acid that function in both an
autocrine and paracrine manner to regulate broad functions.
Prostaglandin-endoperoxidase synthase 2 (Ptgs2; prostaglan-
din G/H synthase, cyclooxygenase 2) is a key enzyme in the
PG biosynthesis pathway, converting arachidonic acid to PG
H2, from which prostacyclin, thromboxane A2, PGD2, PGE2,
and PGF2a are produced by specific synthase enzymes.
Individual PGs often have opposing biological effects. For
example, in the lung, PGE2 causes relaxation, whereas PGD2
causes contraction of bronchial muscle (Goodman et al.,
1996).
Recent studies demonstrate that PGs regulate hair growth.
Increases in PG levels within the epidermis through over-
expression of Ptgs2 cause alopecia and sebaceous hyperplasia,
and may or may not cause a predisposition to squamous cell
tumors (Muller-Decker et al., 1998; Neufang et al., 2001; Bol
et al., 2002). Prostaglandin D2, E2, and F2a metabolism and
signaling proteins are expressed in the hair follicle (Colombe
et al., 2007; Garza et al., 2012). The Food and Drug
Administration (FDA)-approved PGF2a analog, bimatoprost is
used clinically to enhance hair growth of human eyelashes
(Johnstone and Albert, 2002). PGE2 and PGF2a enhance hair
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growth in mice (Geng et al., 1992; Sasaki et al., 2005). In
contrast, PGD2 inhibits hair growth in humans and mice
(Garza et al., 2012), demonstrating the opposing functions of
PGs. PGD2 levels are significantly increased in bald scalp
compared with haired scalp of patients with male pattern hair
loss. Moreover, topically applied exogenous PGD2 inhibits the
hair growth of mice and explants of human hair follicles
through the PGD2–GPR44 signaling pathway (Garza et al.,
2012). These results imply a regulatory network in hair
follicles wherein PGD2 inhibits, whereas PGE2/F2a promote,
hair follicle function.
PGs are key inflammatory mediators involved in wound
healing; however, no study has examined their role in skin
regeneration. We hypothesized that, given their presence
during wound healing, PGs would affect wound-induced hair
follicle neogenesis (WIHN). With reports of PGE2 promoting
regeneration (Goessling et al., 2009), we further hypothesized
that PGD2 would inhibit regeneration. In this study, we
characterize the fluctuations of PGs throughout wound
healing and demonstrate that levels of PGD2 are inversely
correlated with WIHN. Furthermore, we define an
alternatively spliced transcript variant of lipocalin-type PGD2
synthase (Ptgds, L-pgds) that correlates with the regeneration
phenotype among several strains of mice. We demonstrate
that PGD2 inhibits hair follicle regeneration through the
G-protein-coupled receptor Gpr44 (DP-2).
RESULTS
PGD2 and PGE2 are expressed in reciprocal patterns during
wound healing
PG levels during incisional wounding in mice using enzyme
immunoassays have been previously published (Kapoor et al.,
2007). In our study, we measured PGs during full-thickness
excisional wounding in mice by mass spectrometry (Bell-
Parikh et al., 2003). In addition to the absolute PG levels, the
expression of PG synthase enzymes was assessed by
quantitative real-time reverse-transcriptase–PCR (qRT–PCR).
Anesthetized adult C57Bl/6J mice were wounded with a
1 cm2 full-thickness dorsal skin excision down to the level of
skeletal muscle on postnatal day 21 (p21). The epidermis and
dermis at the wound edge were sampled at various time points
before injury to 15 days after injury. Histology revealed the
emergence of an inflammatory infiltrate by postwound day 5
(PWD5). The healed wounds at PWD14 showed thickened
epidermal and dermal layers compared with unwounded
normal skin (Figure 1a). PGE2 and PGF2a levels increased
early in wound healing, whereas PGD2 increased during the
later stages of wound healing (PWD8 and onward; absolute
levels, Figure 1b; relative to baseline, Figure 1c). Matching
the relative levels of their products, mRNA levels of PG
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Figure 1. PGD2 and PGE2 are expressed in reciprocal patterns during wound
healing. (a–d) Full excision skin wounding to the depth of skeletal muscle was
carried out on C57Bl/6J mice. On the listed days, tissue from the wound edge
was sampled for measurement. (a) Hematoxylin and eosin histology of normal
(baseline), 6-hour wound edge, postwound day 5 (PWD5), and 2 days after
scab detached (PWD14); wound edges shown with dashed line (yellow). Scale
bar¼ 100mm. (b, c) Levels of PGD2, PGE2, and PGF2a measured by mass
spectrometry, depicted in either (b) absolute ng g1 tissue or as (c) fold change
in ng g 1 tissue relative to baseline; n¼3; Po0.05. (d) mRNA expression of
Ptgds1 and Ptges1 as determined by quantitative real-time reverse-
transcriptase–PCR; n¼ 3; *Po0.05. PG, prostaglandin.
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synthase enzyme for PGE2 (Ptges) are significantly elevated
during the early phases of wound healing, whereas Ptgds
levels are elevated during the later stages of healing
(Figure 1d).
PGD2 levels inversely correlate with WIHN
To investigate whether PGD2 inhibits hair follicle regeneration
after wounding, we examined PGD2 synthase and actual
PGD2 levels according to regeneration phenotype using three
distinct background strains of mice: C57Bl/6J, FVB/N, and
Mixed (C57Bl/6J FVB/N SJL). Anesthetized adult mice
(p21) were wounded with a 1 cm2 full-thickness dorsal wound
as above. The wound was allowed to heal by contraction and
reepithelialization, which was complete B12 days after
wounding. The resulting visible scar was 2–4 mm2 in size.
The numbers of regenerated hair follicles within the scar were
detected by whole-mount keratin 17 immunohistochemistry
on isolated epidermis between PWD20 and PWD24. Hair
follicles formed within a discrete area of the center of the
scar (Figure 2a). Histology of keratin 17–positive de novo
hair follicles was confirmed with cross-sectional
immunohistochemistry; adjacent sebaceous glands were also
noted (Supplementary Figure S1 online).
Distinct levels of follicle regeneration were quantified
among the different mouse strains, similar to published studies
(Ito et al., 2007). C57Bl/6J mice had the least amount of
follicle regeneration (B5 follicles), whereas the Mixed strain
background had a mean of 20 follicles, a 4-fold increase
in follicle regeneration (Figure 2b). Next, we examined Ptgds
levels among strains. Before the appearance of regenerated
hair follicles at PWD20, mRNA levels of Ptgds were measured
on BPWD12 in the reepithelialized skin. Ptgds levels nega-
tively correlate with regeneration when strain backgrounds are
compared. C57Bl/6J mice had the highest level of Ptgds
mRNA expression and the lowest amount of follicle neogen-
esis (Figure 2c). Conversely, the Mixed strain had the lowest
Ptgds mRNA expression and the highest amount of follicle
neogenesis. Levels of regeneration and Ptgds were both
intermediate in FVB.
Next, we measured the individual levels of PGD2, PGE2,
and PGF2a in reepithelialized skin at PWD12 by mass
spectrometry. The capacity to make PGD2 corresponded to
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Figure 2. Prostaglandin D2 (PGD2) levels negatively correlate with hair follicle regeneration. (a–e) Full excision skin wounding as described in Figure 1 was
carried out on C57Bl/6J, FVB/N, and Mixed strain mice. (a) Hair follicle regeneration was assessed by keratin 17 (K17) immunohistochemistry on isolated
epidermis at postwound days (PWDs) 20–24. Representative images are shown: scar outlined in blue, and wound-induced hair follicle neogenesis (WIHN)
area within in red. Scale bar¼ 100mm. (b) Quantification of regenerated follicles within scars by strain; nX33, *Po0.05. (c) Quantitative real-time
reverse-transcriptase–PCR of prostaglandin D2 synthase (Ptgds) mRNA levels (shown as fold change) in PWD12 reepithelialized skin; n¼ 3, *Po0.05.
(d–f) Mass spectrometry measurement of individual PGs in reepithelialized skin at PWD12. (d) PGD2; (e) PGE2; and (f) PGF2a; n43; *Pp0.05.
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the degree of expression of Ptgds across the strains; PGD2
levels were greatest within C57Bl/6J mice, intermediate within
FVB/N, and lowest in Mixed strain mice (Figure 2d). The levels
of PGE2 and PGF2a did not display a similar pattern and the
levels of PGF2a in skin were 10-fold less than both PGD2 and
PGE2 (Figures 2e and f). PGE2 or PGF2a did not correlate with
regeneration ability across all strains. With no clear positive or
negative correlation to the regeneration phenotype in the
mouse strains, analysis was not continued for PGE2 or PGF2a.
These results demonstrated that the PGD2 pathway, but not
the PGE2 or PGF2a, pathway, correlates with the degree of
wound-induced hair neogenesis; regeneration ability was
inversely related to PGD2 levels.
Ptgds splice variant missing exon 3 correlates with low
regeneration
Given that Ptgds mRNA expression and its product PGD2
negatively correlated with the observed follicle regeneration
among the strains of mice, we focused our investigation on
understanding the location and expression of Ptgds. We
localized Ptgds mRNA and protein within reepithelialized
skin (PWD12) from C57Bl/6J mice. For detection of RNA, we
enzymatically separated epidermis from dermis and quantified
Ptgds mRNA levels by qRT–PCR on each fraction. Ptgds was
more abundant in epidermis than dermis (Figure 3a). Ptgds
was detected by immunohistochemistry predominantly in the
scar epidermis, within the cytoplasm of keratinocytes, rather
than dermis (Figure 3b). There is precedence for Ptgds
expression within epithelial tissues of the retina and gastric
mucosa as well as in keratinocytes of the skin (Takeda et al.,
2006; Hokari et al., 2009; Black et al., 2010; Garza et al.,
2012). Consistent with the sporadic expression of Ptgds we
detected in the dermis, fibroblasts can express Ptgds during
injury and serve as a source of PGD2 (Hokari et al., 2009).
Noting no discernable differences in the location of Ptgds
protein between mouse strains and unable to detect changes
in protein expression by immunoblotting, we investigated the
possibility of alternative splicing of Ptgds as a possible
explanation for lower levels of Ptgds mRNA and its resulting
product, PGD2. We investigated the expression of Ptgds splice
variants in reepithelialized skin at PWD12 of C57Bl/6J,
FVB/N, and Mixed strain mice using Affymetrix exon probes
followed by analysis using Partek Genome Studio software.
We discovered that expression of exon 3 of the Ptgds gene
varied significantly among our strains. Exon 3 expression was
most abundant in C57Bl/6J and least expressed within Mixed
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Figure 3. Splicing of exon 3 in prostaglandin D2 synthase (Ptgds) positively correlates with hair follicle regeneration. (a–e) Newly reepithelialized skin
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strain mice. FVB/N mice demonstrated an intermediate level
of exon 3 expression (Figure 3c). Thus, the expression of exon
3 was inversely correlated with the observed follicle regenera-
tion in each strain (Figures 2a and b). Exons 1, 4, and 5 also
had differential splicing correlating to regeneration ability, but
these differences were of much smaller magnitude; thus, we
focused our further efforts on exon 3. These findings for exon 3
were confirmed with PCR using complementary DNA (cDNA)
from PWD12 reepithelialized skin in separate animals. PCR
primers (Primer Set 1, Supplementary Figure S2 online) not in
common with the Affymetrix probe were selected to border
exon 3 (located within exon 2 and exon 4), thus detecting the
presence or absence of exon 3 (Figure 3d). Two additional
independent primer sets (Primer Sets 2 and 3; Supplementary
Figure S2 online) were also used to validate these results.
Sanger sequencing was carried out on the PCR products
(Primer Sets 1 and 2) and a portion of Ptgds exon 3 was
absent as noted by analysis using BLAST software (Figure 3f).
Furthermore, in Mixed strain mice, additional smaller bands
were detected by PCR with Primer Set 3 (Supplementary
Figure S3 online). DNA sequencing confirmed the absence of
exon 2; thus, we identified a second splice variant of Ptgds
(Supplementary Figure S3 online).
In summary, using Affymetrix probes followed by three
independent sets of primers for traditional PCR with DNA
sequencing, we corroborated our finding that C57Bl/6J mice
have a higher proportion of nonspliced Ptgds, whereas our
Mixed strain mice have a higher proportion of Ptgds missing
exon 3 (Figures 3d–f). In summary, Ptgds is preferentially
spliced in strains of mice with higher levels of follicle
regeneration.
PGD2 inhibits wound-induced hair follicle neogenesis through
Gpr44
Finally, we directly investigated the effect of exogenous PGD2
on regeneration. First, we investigated whether PGD2 inhibits
follicle neogenesis in wild-type mice. Because of higher mean
levels of follicle regeneration, Mixed strain mice were used for
these experiments. After wounding, PGD2 was topically applied
to healing wounds, beginning at PWD7 through 2 days after
scab detachment. De novo hair follicles were assessed as in
Figure 2a. Exogenous PGD2 decreased follicle regeneration in
wild-type mice compared with controls (Figure 4a).
More convincing evidence of PGD2 inhibition of follicle
regeneration was sought using knockout mouse models. PGD2
activity is mediated through binding to two G-protein-coupled
receptors: PGD2 receptor (Ptgdr, DP, DP-1) and Gpr44 (Crth2;
DP-2) (Ricciotti and FitzGerald, 2011). The role of PGD2
signaling was investigated using individual PGD2 receptor
knockout mice, Ptgdr / and Gpr44 / , as well as strain-
matched (C57Bl/6J) control mice. Mice were wounded as
above, with counting of de novo follicles on PWD20 as a
measure of regenerative capacity. qRT-PCR determined that
each of the two receptors was expressed at similar levels in
wild-type mice in normal skin as well as within healed scars.
Previous studies demonstrated Ptgdr and Gpr44 expression
within epidermal and follicular keratinocytes (Colombe et al.,
2008). Mice lacking Ptgdr or Gpr44 receptors are
phenotypically normal, with no observed skin, hair follicle,
or hair cycling defects. There was no difference in follicle
regeneration after wounding between control mice and
Ptgdr / mice. However, in mice lacking Gpr44, follicle
regeneration was significantly increased (B2-fold) compared
with wild-type and Ptgdr / mice; mice that were
heterozygous for Gpr44 had an intermediate level of
regenerated follicles, but were not significantly different from
wild-type or knockout mice (Figure 4b).
We further examined the impact of PGD2 on mice that are
heterozygous or null for Gpr44. Using additional cohorts of
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Figure 4. Prostaglandin D2 (PGD2) inhibits wound-induced hair follicle
neogenesis (WIHN) in wild-type mice but not in Gpr44-null mice, which
otherwise have increased hair follicle regeneration. (a) Full excision wounding
as described in Figure 1 was carried out on Mixed strain mice with topical
application of PGD2 beginning on postwound day 7 (PWD7). Topical
application of PGD2 to wild-type mice decreased WIHN; n¼ 7–9, P¼ 0.06.
(b) Individual prostaglandin receptor null (Ptgdr knockout (KO) and Gpr44
KO), Gpr44þ / , and wild-type (WT; C57BL/6J) mice were subjected to the
WIHN assay and regenerated follicles were detected by keratin 17 (K17)
immunohistochemistry. Gpr44 KO mice had a 2-fold increase in regenerated
follicles compared with wild-type and Ptgdr KO mice; n¼ 21–31 mice/
genotype, *Po0.05. Gpr44þ / mice demonstrated an intermediate level of
regeneration. (c) WIHN assay was performed on Gpr44þ / and Gpr44 KO
mice with topical application of PGD2 beginning at PWD7. Topical
application of PGD2 to both Gpr44
þ / and Gpr44 KO mice had no effect
on WIHN; n¼ 8–12. Similar to b, Gpr44 KO mice demonstrate increased
WIHN compared with Gpr44þ / mice.
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heterozygous and Gpr44 / mice, we evaluated the effect of
PGD2 on WIHN. PGD2 was topically applied to healing
wounds, beginning at PWD7 through 2 days after scab
detachment. Exogenous PGD2 did not significantly affect
follicle regeneration in Gpr44þ / or Gpr44 / mice com-
pared with vehicle control (Figure 4c). As before, follicle
regeneration with vehicle control was increased in null
mice when compared with Gpr44þ / mice, although not
significantly.
The application vehicle for PGD2 used in Figure 4c influ-
enced follicle regeneration; vehicle increased the number of
regenerated follicles in scars by an average of nine follicles
compared with nonvehicle-treated mice (n410; Po0.05) for
Gpr44-null mice. Therefore, comparisons cannot be made
between Figure 4b and c. In addition, results in Figure 4a
cannot be compared with Figure 4b or c because of inherent
variation in the strains.
Together, the ability of exogenous PGD2 to inhibit WIHN in
wild-type mice, the increased level of WIHN in Gpr44-null
mice, and the resistance to PGD2 inhibition of WIHN in
Gpr44 / mice collectively demonstrate that the mechanism
for PGD2 inhibition of WIHN occurs through Gpr44
activation.
DISCUSSION
Wound healing usually results in inadequate tissue repair by
scarring or fibrosis. In some cases, however, tissue regenera-
tion can occur. Our understanding of the control of wound
scarring versus tissue regeneration is incomplete. The con-
tribution of inflammatory mediators, including PGs, during the
wound healing process is well established. PG functions
during tissue regeneration are less studied, but it is known
that PGE2 can stimulate liver regeneration (Goessling et al.,
2009). Given the demonstration of increased hair growth
by PGF2a and PGE2 (Geng et al., 1992; Sasaki et al., 2005),
and decreased hair growth by PGD2 (Garza et al., 2012), we
hypothesized that these PGs may be important in regulating
hair neogenesis in WIHN. Normal hair growth is regulated
by transition between catagen, anagen, and telogen phases
of the hair cycle. During anagen, the hair follicle partially
regenerates, suggesting that the pathways that control the
hair regeneration cycle may also control hair follicle
neogenesis. In this article, we demonstrated that PGD2
correlates with decreased follicle regeneration after
wounding, that PGD2 has the capacity to inhibit follicle
regeneration, and that the mechanism of this inhibition is
through the Gpr44 receptor.
One previously unreported discovery is that Ptgds is alter-
natively spliced, such that partial removal of exon 3 correlates
with higher levels of regeneration. The absence of exon 3
likely affects the functionality of the final product. The
structure of Ptgds is that of the typical lipocalin b-barrel
comprising eight antiparallel b-barrel strands, three a-helical
regions, and a C-terminal b-strand. Ptgds is the only enzyme
within the lipocalin family of proteins; it catalyzes the
formation of PGD2 from PGH2. Like other lipocalin family
members, Ptgds also functions as a transport protein for
lipophilic compounds, such as retinoids, gangliosides,
bilirubin, and b-amyloid peptides (Akerstrom et al., 2000).
Exon 3 of Ptgds encodes amino acids 86 through 110 of the
protein sequence, forming the D and E strands (Shimamoto
et al., 2007). The E strand, together with the F strand, forms the
flexible E–F loop responsible for the open/closed formations of
the calyx. On the basis of our sequence results, 20 amino
acids are removed from exon 3, including Leu96 and Cys89.
Leu96 in exon 3, with its bulky side chain, along with other
nearby hydrophobic amino acids, acts to divide the central
cavity into two compartments: one compartment binds and
converts PGH2 to PGD2, whereas the other compartment
binds lipophilic compounds, such as retinoids (Kumasaka
et al., 2009). Cys89 in exon 3 forms a disulfide bridge with
Cys186, which is important in stabilizing the protein structure.
In all, exon 3 encodes amino acids involved in central cavity
division, open/closed conformation formation, and protein
stability.
We also identified a splice variant of Ptgds that completely
lacks exon 2 (Supplementary Figure S3 online). Four key
serine, theronine, and cysteine moieties are located within
exon 2 and mutations within these residues markedly decrease
Ptgds enzymatic activity (Shimamoto et al., 2007). Alternative
splicing of Ptgds, such that portions of exon 2 or exon 3 are
absent, may result in decreased functionality of Ptgds and
contribute to the lower level of PGD2 found in the strains
expressing spliced Ptgds. In support of this hypothesis, an
alternative splice variant of cyclooxygenase 1 lacking 37
amino acids in exon 9 results in no detectable PGH2
product (Schneider et al., 2005). Conversely, splice variants
of receptor and enzymes can exert dominant negative effects
over their complete signaling and catalytically active forms
(Stamm et al., 2005).
We also found that during wound healing, the capacity of
tissue to generate PGE2 and PGD2 is separated over time, thus
providing evidence consistent with the distinct functions of
PGs. These results are similar to those observed after incisional
wound healing in DBA/I mice (Kapoor et al., 2007). In C57Bl/
6J and DBA/I strains and models of wound healing, PGE2 is
the more abundant product during the early phases of wound
healing. Elevated levels of PGE2, a potent immune activator,
are consistent with progressing inflammation (Sakata et al.,
2010). Whereas, at later stages, when inflammation is
resolving, PGE2 levels taper off and PGD2 becomes the
predominant PG.
Our final previously unreported finding was that the
mechanism of PGD2 inhibition of wound-induced hair neo-
genesis is through the Gpr44 receptor. Gpr44 is expressed on
immune cells including eosinophils, neutrophils, mast cells,
basophils, a subpopulation of memory Th2 cells, and mono-
cytes (Nagata et al., 1999a, b). It mediates the chemotaxis of
these proinflammatory cells during allergic inflammation
(Hirai et al., 2001). Our results show that in the absence of
Gpr44, WIHN is increased in our experimental wound model,
which suggests that follicle regeneration is possible in the
absence of this proinflammatory milieu of cells. Similarly,
WIHN is suppressed in wild-type mice in the presence of
PGD2, arguing that the presence of proinflammatory
mediators inhibits regeneration.
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Although these data suggest that Gpr44 normally inhibits
WIHN through recruitment of inflammatory cells, alternative
interpretations are possible. Gpr44-null mice show features of
both enhanced and decreased airway inflammation (Chevalier
et al., 2005; Shiraishi et al., 2008). Conflicting data in the
literature demonstrate that PGD2 both enhances and reduces
allergic responses, with the Gpr44 receptor having a critical
role (Matsuoka et al., 2000; Arimura et al., 2001; Satoh et al.,
2006; Trivedi et al., 2006; Hammad et al., 2007; Shiraishi
et al., 2008; Matsushima et al., 2011; Yamamoto et al., 2011).
Therefore, it is also possible that the actions of PGD2 through
Gpr44 may inhibit proregenerative immune factors.
A motivation for this study is the ability of PGD2 to inhibit
hair lengthening (Garza et al., 2012). Here we demonstrate
that PGD2 also inhibits hair regeneration after wounding.
Thus, PGD2 and Gpr44 inhibition of the hair follicle occurs in
multiple contexts and may be exploited in future therapies.
Pharmaceutical companies are already focused on the
development of Gpr44-selective antagonists for the treatment
of asthma with at least nine other known Gpr44 antagonists in
phase II clinical trials (Jones et al., 2009; Norman, 2010;
Pettipher and Whittaker, 2012). In addition to previous studies
suggesting that Gpr44 antagonists may be beneficial in
androgenetic alopecia, our results suggest that formulations
of Gpr44 antagonists may decrease scarring during wound
healing. A specific example is ramatroban, an orally
active, dual Gpr44, and thromboxane A2 receptor
antagonist, which is approved in Japan for the treatment of
allergic rhinitis in humans (Sugimoto et al., 2003). Future
studies could examine the effect of ramatroban in stimulating
hair follicle neogenesis.
MATERIALS AND METHODS
Animals
All animal protocols were approved by the Johns Hopkins University
Animal Care and Use Committee. C57Bl/6J, FVB/N, and Mixed strain
(C57Bl/6J FVB/N SJL/J) animals were obtained from The Jackson
Laboratory (Bar Harbor, ME) and George Cotsarelis (University of
Pennsylvania). Ptgdr / , Gpr44  / , and Ptgds / knockout mice
were obtained from original sources as previously described (Garza
et al., 2012). Heterozygous mice for Gpr44 were bred by crossing
wild-type and Gpr44 / animals; genotype was verified by PCR
with the following primers: 50-CTCGCCGGACACGCTGAACTTGT-30,
50-TGGGGTCAAACTCAGCTCCTCACG-30, and 50-GCGGCGGCTAA
CAAGTCGGATAG-30. All animal colonies were maintained within
animal facilities with standard humidity, 12-hour light/dark cycle, and
laboratory diet ad libitum. Both male and female mice were used in
our experiments and gender did not affect our results.
WIHN assay
A 1 cm2 full-thickness wound on the backs of 21-day-old male and
female mice was performed as previously described (Ito et al., 2007).
Scars were harvested 8–12 days after the scab detached from the
wound (PWD20–24). This time point represents that B16 days after
contraction has ended and B14 days after reepithelialization has
occurred. The dermis and epidermis were separated using overnight
EDTA treatment and stained for keratin 17 (Abcam, Cambridge, MA)
on whole-mount epidermis to identify regenerated hair follicles.
Numbers of regenerated follicles were quantified in the reepithelia-
lized skin as published (Ito et al., 2007).
Mass spectrometry
Baseline tissue, a 1-cm2 piece of full-thickness skin, was taken from
each animal at wounding. Wound edges from 1 hour, 1 day, 3 days,
and 5 days after wounding and reepithelialized tissue (healed scar) at
PWD12, PWD14, and PWD16 were collected for analysis. All
samples were collected in acetone, frozen in liquid nitrogen, and
stored at  80 1C. PGs were isolated from samples by tissue
homogenization in acetone for 90 seconds. Samples were centrifuged
at 13,500 r.p.m. at 4 1C for 10 minutes and the resulting supernatant
was assessed for PGD2, PGE2, and PGF2a levels by mass spectrometry
as described (Garza et al., 2012).
qRT-PCR
The levels of gene expression were accessed by qRT-PCR in a parallel
time course to that of mass spectrometry. For mRNA analysis, samples
were collected and stored in RNA Later (Sigma, St Louis, MO) at
 20 1C. Early time points contained wound-edge only (B1–2 mm
border) and time points after reepithelialization consisted of the ‘‘scar
area’’ only. Samples were homogenized using a tissue grinder,
processed with RNeasy Fibrous Tissue kit (Qiagen, Valencia, CA)
and transcribed to cDNA (High Capacity RNA to cDNA; Applied
Biosystems, Carlsbad, CA). qRT-PCR was performed on samples
(50 ng cDNA) for genes of interest using inventoried TaqMan gene
expression assays from Applied Biosystems. Differences in gene
expression were assessed by comparative DDCT values with fold
change calculations.
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed, paraffin-
embedded mouse skin sections using the avidin–biotin complex
method and AEC development (ABC kit and AEC Substrate kit for
Peroxidase; Vector Laboratories, Burlingame, CA). Baseline and
BPWD12 healed scars were subjected to deparaffinization, rehydra-
tion, and antigen retrieval with TRILOGY buffer (Cell Marque,
Rocklin, CA) before immunohistochemistry. Sections were incubated
overnight with rabbit polyclonal Ptgds antibody (LifeSpan Bio-
sciences, Seattle, WA). For Supplementary Figure S1 online, Cytoker-
atin 17 (Abcam) was used. Negative controls were prepared with
purified rabbit IgG antibody (Invitrogen, Camarillo, CA). Sections
were counterstained with hematoxylin using standard procedures.
Ptgds splice variant analysis
Splice variant analysis among mouse strains within Ptgds gene were
identified and analyzed using Partek Genome Studio software (Partek,
St Louis, MO). Splice variant expression within the third exon was
confirmed by standard PCR and agarose gel electrophoresis. Primers
used were as follows: sense 50-AGGGCCATGACACAGTGCAGC-30
and antisense 50-GAGGGTGGCCATGCGGAAGTC-30 (Primer Set 1),
which identify a 371-bp amplicon for the complete exon 3 compared
with a 300-bp amplicon if exon 3 is affected. These initial PCR results
were confirmed by two additional primer sets: Primer Set 2 with
amplicons 371 and 300, respectively, 50-AGGGCCATGACACAGTG
CAGCCCAACTTTC-30 and 50-GAGGGTGGCCATGCGGAAGTCCTG
GCCTGGG-30; and Primer Set 3, 50-AAGACAAGTTCCTGG
GGCGCTG-30 and 50-GTGGATGCTGCCCGAGTGGG-30 (amplicons
AM Nelson et al.
Prostaglandins and Wound Healing
www.jidonline.org 887
of B240 vs. B180 with exon 3 splicing). See Supplementary Figure
S3 online for all primer locations. cDNA was subjected to PCR with
PCR MasterMix (Promega, Madison, WI) and Veriti Thermal Cycler
(Applied Biosystems). Relative quantification of PCR results was
assessed using ImageJ NIH software.
Topical PGD2 treatment
PGD2 (Cayman Chemical, Ann Arbor, MI) was reconstituted
in ethanol at a concentration of 50 mg ml 1. Then, 10mg PGD2 in
ethanol/5% polyethylene glycol/2% glycerol was applied daily
beginning on PWD7 and continued daily till 2 days after scab
detachment. Ethanol/polyethylene glycol/glycerol alone was applied
in parallel for vehicle control. Regenerated hair follicles were
assessed by keratin 17 immunohistochemistry at PWD20–24.
Statistical analysis
Each experiment was repeated with at least three independent litters
of animals. Numbers of independent animals were noted for each
experiment. Data were analyzed using paired t-test or analysis of
variance single factor. Statistical significance was considered at
Po0.05.
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